Incidence of VTE during follow-up intervals, overall, and by cancer type
| . | . | 6 mo prior to cancer diagnosis/index date . | 6 mo after cancer diagnosis/index date . | 12 mo after cancer diagnosis/index date . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of persons . | Period prevalence (95% CI) . | Rate per 1000 person-years (95% CI) . | HR* (95% CI) . | Cumulative incidence (95% CI) . | Incidence rate per 1000 person-years (95% CI) . | HR* (95% CI) . | Cumulative incidence (95% CI) . | Incidence rate per 1000 person-years (95% CI) . | HR* (95% CI) . | |
| Comparison cohort | 1 497 276 | 0.16 (0.15-0.16) | 3.2 (3.0-3.3) | Ref | 0.19 (0.18-0.19) | 3.7 (3.6-3.9) | Ref | 0.35 (0.34-0.36) | 3.6 (3.5-3.7) | Ref |
| Cancer cohort | 499 092 | 0.93 (0.90-0.96) | 18.6 (18.1-19.2) | 6.0 (5.7-6.3) | 1.69 (1.66-1.73) | 39.0 (38.2-39.9) | 11.1 (10.5-11.6) | 2.28 (2.24-2.32) | 28.4 (27.9-29.0) | 8.5 (8.2-8.8) |
| Cancer groups | ||||||||||
| Pancreatic | 16 044 | 3.02 (2.76-3.29) | 60.5 (55.1-65.9) | 15.3 (12.1-19.2) | 4.43 (4.12-4.76) | 156.0 (144.4-167.5) | 50.4 (36.5-69.6) | 5.50 (5.15-5.87) | 133.3 (124.4-142.1) | 41.7 (32.1-54.2) |
| Ovarian | 10 565 | 2.25 (1.98-2.55) | 45.1 (39.3-50.9) | 20.5 (14.0-30.2) | 3.10 (2.78-3.44) | 71.8 (64.0-79.6) | 30.7 (21.0-45.1) | 3.94 (3.58-4.32) | 49.3 (44.6-54.1) | 20.2 (15.3-26.6) |
| Biliary | 2 611 | 1.80 (1.34-2.38) | 36.1 (25.7-46.5) | 19.5 (8.1-47.5) | 2.90 (2.31-3.60) | 87.2 (67.4-106.9) | 40.5 (15.6-105.4) | 3.78 (3.09-4.56) | 71.2 (57.0-85.4) | 27.0 (13.9-52.5) |
| HL | 2 459 | 0.60 (0.34-0.98) | 11.9 (5.7-18.2) | 10.5 (2.7-41.4) | 2.88 (2.27-3.61) | 60.5 (46.3-74.7) | 95.8 (22.9-401.2) | 3.77 (3.06-4.59) | 41.3 (32.8-49.8) | 60.7 (21.7-169.2) |
| MM | 6 693 | 1.03 (0.81-1.30) | 20.7 (15.8-25.6) | 5.4 (3.6-8.3) | 2.84 (2.46-3.26) | 64.7 (55.4-74.0) | 20.3 (13.3-31.1) | 3.80 (3.36-4.28) | 46.8 (41.0-52.6) | 13.4 (9.8-18.3) |
| Liver | 6 103 | 3.41 (2.97-3.89) | 68.4 (59.0-77.7) | 24.0 (14.6-39.4) | 2.82 (2.42-3.26) | 103.6 (88.0-119.1) | 23.1 (13.4-39.8) | 3.37 (2.94-3.85) | 81.6 (70.4-92.9) | 18.0 (11.5-28.1) |
| NHL | 18 473 | 1.19 (1.04-1.36) | 23.9 (20.7-27.1) | 8.1 (6.2-10.6) | 2.66 (2.43-2.90) | 59.5 (54.2-64.8) | 20.1 (15.5-26.0) | 3.22 (2.97-3.49) | 38.6 (35.5-41.7) | 14.8 (12.0-18.1) |
| NSCLC | 63 548 | 1.60 (1.50-1.70) | 31.9 (30.0-33.9) | 9.7 (8.5-11.1) | 2.60 (2.48-2.73) | 74.4 (70.8-78.0) | 20.0 (17.4-22.9) | 3.31 (3.17-3.45) | 59.0 (56.5-61.6) | 17.4 (15.5-19.6) |
| Stomach | 10 296 | 0.97 (0.79-1.17) | 19.3 (15.5-23.2) | 8.1 (5.4-12.3) | 2.48 (2.19-2.80) | 66.4 (58.2-74.6) | 20.1 (14.0-28.9) | 3.18 (2.85-3.53) | 51.5 (45.9-57.2) | 16.5 (12.3-22.1) |
| Colon | 51 436 | 1.08 (0.99-1.17) | 21.6 (19.8-23.4) | 6.0 (5.2-7.0) | 2.21 (2.09-2.34) | 51.9 (48.9-55.0) | 12.8 (11.2-14.7) | 2.84 (2.70-2.99) | 36.0 (34.1-37.9) | 9.5 (8.5-10.5) |
| Brain | 8 500 | 0.37 (0.26-0.52) | 7.5 (4.8-10.1) | 3.6 (2.0-6.4) | 2.18 (1.88-2.51) | 54.6 (46.7-62.5) | 23.0 (14.7-35.9) | 3.32 (2.96-3.73) | 50.3 (44.4-56.2) | 19.9 (14.2-27.8) |
| Kidney | 12 333 | 1.52 (1.32-1.75) | 30.5 (26.1-34.9) | 10.4 (7.6-14.2) | 2.17 (1.92-2.44) | 51.2 (45.0-57.3) | 22.3 (15.4-32.3) | 2.66 (2.38-2.95) | 34.2 (30.5-38.0) | 10.7 (8.4-13.7) |
| Esophageal | 7 956 | 0.86 (0.67-1.08) | 17.2 (13.1-21.3) | 5.9 (3.7-9.3) | 2.16 (1.86-2.50) | 58.1 (49.4-66.8) | 21.2 (13.4-33.4) | 3.00 (2.64-3.40) | 51.5 (44.9-58.1) | 15.7 (11.2-22.0) |
| Rectal | 26 191 | 0.51 (0.43-0.61) | 10.3 (8.5-12.0) | 3.1 (2.4-3.9) | 2.07 (1.90-2.25) | 45.5 (41.7-49.4) | 12.0 (9.9-14.7) | 2.81 (2.61-3.01) | 32.9 (30.5-35.3) | 9.8 (8.4-11.5) |
| Bladder | 16 051 | 0.71 (0.59-0.86) | 14.3 (11.6-16.9) | 4.8 (3.5-6.5) | 1.66 (1.47-1.87) | 37.8 (33.2-42.4) | 8.9 (6.9-11.4) | 2.74 (2.50-3.01) | 34.5 (31.3-37.8) | 8.6 (7.1-10.4) |
| SCLC | 11 536 | 0.73 (0.58-0.90) | 14.6 (11.4-17.7) | 6.9 (4.5-10.6) | 1.50 (1.29-1.73) | 43.0 (36.6-49.5) | 14.8 (10.0-21.9) | 2.24 (1.98-2.53) | 40.3 (35.4-45.3) | 16.1 (11.6-22.4) |
| Cervical | 7 701 | 0.68 (0.52-0.89) | 13.7 (9.9-17.4) | 7.9 (4.5-14.1) | 1.49 (1.24-1.79) | 31.5 (25.7-37.3) | 20.6 (11.8-36.1) | 2.02 (1.72-2.36) | 22.2 (18.7-25.7) | 17.2 (11.1-26.7) |
| Uterine | 13 656 | 0.75 (0.61-0.91) | 15.0 (12.0-17.9) | 6.4 (4.4-9.3) | 1.43 (1.24-1.65) | 30.1 (25.9-34.4) | 10.8 (7.8-14.9) | 1.98 (1.76-2.23) | 21.5 (18.9-24.1) | 6.9 (5.5-8.7) |
| Leukemia | 14 841 | 0.99 (0.84-1.17) | 19.9 (16.6-23.1) | 6.4 (4.8-8.7) | 1.27 (1.10-1.47) | 29.8 (25.5-34.0) | 9.6 (7.1-13.0) | 1.74 (1.54-1.97) | 21.9 (19.2-24.6) | 6.5 (5.2-8.2) |
| Prostate | 68 334 | 0.73 (0.67-0.79) | 14.6 (13.3-15.9) | 3.8 (3.3-4.4) | 0.80 (0.73-0.87) | 16.5 (15.1-17.9) | 3.8 (3.3-4.3) | 1.21 (1.13-1.30) | 12.9 (12.0-13.8) | 3.0 (2.7-3.3) |
| Testicular | 5 946 | 0.43 (0.29-0.63) | 8.7 (5.3-12.1) | 7.1 (3.3-15.4) | 0.80 (0.60-1.05) | 16.1 (11.5-20.8) | 22.5 (8.8-57.7) | 1.29 (1.02-1.61) | 13.2 (10.2-16.1) | 18.0 (9.4-34.2) |
| Breast | 85 746 | 0.22 (0.19-0.25) | 4.3 (3.7-5.0) | 1.8 (1.5-2.2) | 0.64 (0.59-0.70) | 13.2 (12.1-14.3) | 4.5 (3.9-5.1) | 1.00 (0.94-1.07) | 10.5 (9.8-11.2) | 3.7 (3.3-4.1) |
| Melanoma | 32 073 | 0.21 (0.16-0.26) | 4.1 (3.1-5.1) | 2.5 (1.7-3.5) | 0.36 (0.30-0.43) | 7.3 (6.0-8.7) | 2.9 (2.2-3.8) | 0.63 (0.55-0.73) | 6.5 (5.6-7.4) | 2.5 (2.1-3.0) |
| . | . | 6 mo prior to cancer diagnosis/index date . | 6 mo after cancer diagnosis/index date . | 12 mo after cancer diagnosis/index date . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of persons . | Period prevalence (95% CI) . | Rate per 1000 person-years (95% CI) . | HR* (95% CI) . | Cumulative incidence (95% CI) . | Incidence rate per 1000 person-years (95% CI) . | HR* (95% CI) . | Cumulative incidence (95% CI) . | Incidence rate per 1000 person-years (95% CI) . | HR* (95% CI) . | |
| Comparison cohort | 1 497 276 | 0.16 (0.15-0.16) | 3.2 (3.0-3.3) | Ref | 0.19 (0.18-0.19) | 3.7 (3.6-3.9) | Ref | 0.35 (0.34-0.36) | 3.6 (3.5-3.7) | Ref |
| Cancer cohort | 499 092 | 0.93 (0.90-0.96) | 18.6 (18.1-19.2) | 6.0 (5.7-6.3) | 1.69 (1.66-1.73) | 39.0 (38.2-39.9) | 11.1 (10.5-11.6) | 2.28 (2.24-2.32) | 28.4 (27.9-29.0) | 8.5 (8.2-8.8) |
| Cancer groups | ||||||||||
| Pancreatic | 16 044 | 3.02 (2.76-3.29) | 60.5 (55.1-65.9) | 15.3 (12.1-19.2) | 4.43 (4.12-4.76) | 156.0 (144.4-167.5) | 50.4 (36.5-69.6) | 5.50 (5.15-5.87) | 133.3 (124.4-142.1) | 41.7 (32.1-54.2) |
| Ovarian | 10 565 | 2.25 (1.98-2.55) | 45.1 (39.3-50.9) | 20.5 (14.0-30.2) | 3.10 (2.78-3.44) | 71.8 (64.0-79.6) | 30.7 (21.0-45.1) | 3.94 (3.58-4.32) | 49.3 (44.6-54.1) | 20.2 (15.3-26.6) |
| Biliary | 2 611 | 1.80 (1.34-2.38) | 36.1 (25.7-46.5) | 19.5 (8.1-47.5) | 2.90 (2.31-3.60) | 87.2 (67.4-106.9) | 40.5 (15.6-105.4) | 3.78 (3.09-4.56) | 71.2 (57.0-85.4) | 27.0 (13.9-52.5) |
| HL | 2 459 | 0.60 (0.34-0.98) | 11.9 (5.7-18.2) | 10.5 (2.7-41.4) | 2.88 (2.27-3.61) | 60.5 (46.3-74.7) | 95.8 (22.9-401.2) | 3.77 (3.06-4.59) | 41.3 (32.8-49.8) | 60.7 (21.7-169.2) |
| MM | 6 693 | 1.03 (0.81-1.30) | 20.7 (15.8-25.6) | 5.4 (3.6-8.3) | 2.84 (2.46-3.26) | 64.7 (55.4-74.0) | 20.3 (13.3-31.1) | 3.80 (3.36-4.28) | 46.8 (41.0-52.6) | 13.4 (9.8-18.3) |
| Liver | 6 103 | 3.41 (2.97-3.89) | 68.4 (59.0-77.7) | 24.0 (14.6-39.4) | 2.82 (2.42-3.26) | 103.6 (88.0-119.1) | 23.1 (13.4-39.8) | 3.37 (2.94-3.85) | 81.6 (70.4-92.9) | 18.0 (11.5-28.1) |
| NHL | 18 473 | 1.19 (1.04-1.36) | 23.9 (20.7-27.1) | 8.1 (6.2-10.6) | 2.66 (2.43-2.90) | 59.5 (54.2-64.8) | 20.1 (15.5-26.0) | 3.22 (2.97-3.49) | 38.6 (35.5-41.7) | 14.8 (12.0-18.1) |
| NSCLC | 63 548 | 1.60 (1.50-1.70) | 31.9 (30.0-33.9) | 9.7 (8.5-11.1) | 2.60 (2.48-2.73) | 74.4 (70.8-78.0) | 20.0 (17.4-22.9) | 3.31 (3.17-3.45) | 59.0 (56.5-61.6) | 17.4 (15.5-19.6) |
| Stomach | 10 296 | 0.97 (0.79-1.17) | 19.3 (15.5-23.2) | 8.1 (5.4-12.3) | 2.48 (2.19-2.80) | 66.4 (58.2-74.6) | 20.1 (14.0-28.9) | 3.18 (2.85-3.53) | 51.5 (45.9-57.2) | 16.5 (12.3-22.1) |
| Colon | 51 436 | 1.08 (0.99-1.17) | 21.6 (19.8-23.4) | 6.0 (5.2-7.0) | 2.21 (2.09-2.34) | 51.9 (48.9-55.0) | 12.8 (11.2-14.7) | 2.84 (2.70-2.99) | 36.0 (34.1-37.9) | 9.5 (8.5-10.5) |
| Brain | 8 500 | 0.37 (0.26-0.52) | 7.5 (4.8-10.1) | 3.6 (2.0-6.4) | 2.18 (1.88-2.51) | 54.6 (46.7-62.5) | 23.0 (14.7-35.9) | 3.32 (2.96-3.73) | 50.3 (44.4-56.2) | 19.9 (14.2-27.8) |
| Kidney | 12 333 | 1.52 (1.32-1.75) | 30.5 (26.1-34.9) | 10.4 (7.6-14.2) | 2.17 (1.92-2.44) | 51.2 (45.0-57.3) | 22.3 (15.4-32.3) | 2.66 (2.38-2.95) | 34.2 (30.5-38.0) | 10.7 (8.4-13.7) |
| Esophageal | 7 956 | 0.86 (0.67-1.08) | 17.2 (13.1-21.3) | 5.9 (3.7-9.3) | 2.16 (1.86-2.50) | 58.1 (49.4-66.8) | 21.2 (13.4-33.4) | 3.00 (2.64-3.40) | 51.5 (44.9-58.1) | 15.7 (11.2-22.0) |
| Rectal | 26 191 | 0.51 (0.43-0.61) | 10.3 (8.5-12.0) | 3.1 (2.4-3.9) | 2.07 (1.90-2.25) | 45.5 (41.7-49.4) | 12.0 (9.9-14.7) | 2.81 (2.61-3.01) | 32.9 (30.5-35.3) | 9.8 (8.4-11.5) |
| Bladder | 16 051 | 0.71 (0.59-0.86) | 14.3 (11.6-16.9) | 4.8 (3.5-6.5) | 1.66 (1.47-1.87) | 37.8 (33.2-42.4) | 8.9 (6.9-11.4) | 2.74 (2.50-3.01) | 34.5 (31.3-37.8) | 8.6 (7.1-10.4) |
| SCLC | 11 536 | 0.73 (0.58-0.90) | 14.6 (11.4-17.7) | 6.9 (4.5-10.6) | 1.50 (1.29-1.73) | 43.0 (36.6-49.5) | 14.8 (10.0-21.9) | 2.24 (1.98-2.53) | 40.3 (35.4-45.3) | 16.1 (11.6-22.4) |
| Cervical | 7 701 | 0.68 (0.52-0.89) | 13.7 (9.9-17.4) | 7.9 (4.5-14.1) | 1.49 (1.24-1.79) | 31.5 (25.7-37.3) | 20.6 (11.8-36.1) | 2.02 (1.72-2.36) | 22.2 (18.7-25.7) | 17.2 (11.1-26.7) |
| Uterine | 13 656 | 0.75 (0.61-0.91) | 15.0 (12.0-17.9) | 6.4 (4.4-9.3) | 1.43 (1.24-1.65) | 30.1 (25.9-34.4) | 10.8 (7.8-14.9) | 1.98 (1.76-2.23) | 21.5 (18.9-24.1) | 6.9 (5.5-8.7) |
| Leukemia | 14 841 | 0.99 (0.84-1.17) | 19.9 (16.6-23.1) | 6.4 (4.8-8.7) | 1.27 (1.10-1.47) | 29.8 (25.5-34.0) | 9.6 (7.1-13.0) | 1.74 (1.54-1.97) | 21.9 (19.2-24.6) | 6.5 (5.2-8.2) |
| Prostate | 68 334 | 0.73 (0.67-0.79) | 14.6 (13.3-15.9) | 3.8 (3.3-4.4) | 0.80 (0.73-0.87) | 16.5 (15.1-17.9) | 3.8 (3.3-4.3) | 1.21 (1.13-1.30) | 12.9 (12.0-13.8) | 3.0 (2.7-3.3) |
| Testicular | 5 946 | 0.43 (0.29-0.63) | 8.7 (5.3-12.1) | 7.1 (3.3-15.4) | 0.80 (0.60-1.05) | 16.1 (11.5-20.8) | 22.5 (8.8-57.7) | 1.29 (1.02-1.61) | 13.2 (10.2-16.1) | 18.0 (9.4-34.2) |
| Breast | 85 746 | 0.22 (0.19-0.25) | 4.3 (3.7-5.0) | 1.8 (1.5-2.2) | 0.64 (0.59-0.70) | 13.2 (12.1-14.3) | 4.5 (3.9-5.1) | 1.00 (0.94-1.07) | 10.5 (9.8-11.2) | 3.7 (3.3-4.1) |
| Melanoma | 32 073 | 0.21 (0.16-0.26) | 4.1 (3.1-5.1) | 2.5 (1.7-3.5) | 0.36 (0.30-0.43) | 7.3 (6.0-8.7) | 2.9 (2.2-3.8) | 0.63 (0.55-0.73) | 6.5 (5.6-7.4) | 2.5 (2.1-3.0) |
HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NSCLC, non–small cell lung carcinoma; Ref, reference group; SCLC, Small-cell lung carcinoma
HR compared with matched-comparison cohort and adjusted for matching factors, Charlson Comorbidity Index score, and congestive heart failure, atherosclerosis, peripheral vascular disease, chronic obstructive pulmonary disease, inflammatory bowel disease, liver diseases, chronic kidney disease, diabetes, obesity, alcohol-related diseases, and hypertension.